Targeted Therapies For Treatment of Lung Cancer – Recent Advances

Foziya Khan¹, S.S. Sisodia²

¹Department of Pharmacology, M. Pharm, Bhupal Noble’s University, Udaipur- 313001, Rajasthan, India
²Department of Pharmacology, Principal of Institution, Bhupal Noble’s University, Udaipur- 313001, Rajasthan, India

Abstract

In both men and women, Lung cancer is the number one cause of cancer-related death. The disorder is especially difficult to detect, and often develops for elderly patients at an advanced stage. Within a year of treatment, more than half of those diagnosed with lung cancer die and 5-year survival is less than 18%. Majority of all lung cancer cases are attributed to Non Small Cell Lung Cancer. Significant advancements in research and diagnosis over the past 10 years have though, culminated in the first improvements made in lung cancer survival. New developments in lung cancer’s cellular pathogenesis and biological activity have culminated in the advancement of rationally developed approaches for early detection, prevention, and treatment of this illness. There are currently several novel treatments in clinical practice, including those that target actionable mutations and more recently immunotherapy. This review will outline developments and emerging debates in lung cancer treatment.

Keywords:
Oncogenes, Mutations, Prevention, Angiogenesis, Management

1 Introduction

Lung cancer is the world’s second-largest cause of death, with an estimated 9.6 million deaths in 2018. It can be broadly classified into two groups: Small Cell Lung Cancer (SCLC), which accounts for roughly 20-25% of bronchiogenic carcinomas and Non Small Cell Lung Cancer (NSCLC), almost all of the remainder (75-80%)¹. NSCLC is further categorized into three types: squamous cell carcinoma, adenocarcinoma, and large cell carcinoma².

Adenocarcinoma is the most prevalent subtype which accounts for about 40% of all lung cancer, which develops gradually and typically arises in the outer peripheral areas of the lungs³. Squamous-cell carcinoma accounts for 25–30% of all cases of lung cancer. It is a very slow-growing type of NSCLC that often occurs in one of the bronchi (lung airways)⁴. Large cell (undifferentiated) carcinoma accounts for 5–10% of lung cancers. It is the rarest subtype of NSCLC, which is growing rapidly and more likely to spread⁵.

2 Risk Assessment, Early Detection and Prevention

The most important source of carcinogens and tumor promoters is cigarette smoking which accounts for about 90% of the cases in men and 70% of the cases in women⁶. Epidemiological studies find a nearly 2-fold increased risk due to a family history of lung cancer following the management of the sensitivity to tobacco smoke⁷. A substantial chance of developing passive smoking lung cancer was measured to be 1.14 to 5.20 in people who had never smoked but lived with a smoker based on meta-analysis and thorough study⁸. Radon, a naturally occurring poison, is one of the contributing factors associated with lung cancer, and around 21,000 lung cancer deaths in the United States have been linked with Radon toxicity⁹.

Lung cancer is hard to detect and is often detected late, only when signs become clinically evident¹⁰. Signs and symptoms of lung cancer include dyspnea (shortness of breath), hemoptysis (coughing up blood), chronic coughing or change in regular coughing pattern, wheezing, chest pain or pain in the abdomen, cachexia (weight loss), fatigue, and loss of appetite, dysphonia (hoarse voice), clubbing of the fingernails (uncommon), dysphasia (difficulty swallowing).
Identifying molecular biomarkers for lung cancer in sputum and blood is an area of active research that offers potentially useful tests to complement radiological imaging and bronchoscopy for screening and early diagnosis.11

Big molecular variations in the pathogenesis of lung cancer include growth factors, receptors and activation of GRP/BN proto-oncogenes and their receptors, IGF, HGF, and their receptor MET, EGFR, HER2/neu12, RAS mutations, MYC amplification and deregulated expression, abnormal expression of BCL-2, cyclin D1 expression, lack of tumor suppressor genes, aberrant methylation leading to loss of gene expression, tumor development due to stimulation of tumor-induced angiogenesis, expression of telomerase function, cell immortality and likely failure of DNA repair mechanism.11 Emerging genomic and proteomic innovations have led to the discovery of observable biomarkers in blood with possible clinical applications.13

Future studies strongly require assessing the therapeutic utility of molecular biomarkers in sputum and blood for monitoring and early diagnosis.

Furthermore, the introduction of screening tests into clinical practice will classify patients at high risk for developing lung cancer (based on irregular results from CT imaging, bronchoscopy, and/or biomarker profiling), and appropriate approaches for selective treatment and surveillance of these individuals will need to be formulated and enforced.

3 Novel Targeted Or Personalised Targeted Therapies

Treatment for non small cell lung cancer (NSCLC) has advanced in the last decade. Although early diagnosis and surgical treatment contribute to better patient outcomes, most patients are diagnosed with lung cancer at later stages, which are essentially incurable and often need multimodal therapy. Over the past decade, significant improvements in the treatment of advanced stages have been identified largely due to increased knowledge of the molecular complexity and mechanisms of the onset and development of lung cancer, as well as advances in radio and surgical therapies. Different roles for selective therapies arise as standard first- or second-line treatments in patients with identified mutations from clinical trials. Some experimental medicines have been developed specifically for these key components (Figure 1 and Table 1), and clinical trials have shown promising results so far.

3.1 EGFR pathway inhibitors

EGFR is a cell-surface tyrosine kinase receptor that can activate cell growth and proliferation pathways when activated. For cancers, EGFR mutations generate unregulated cell division through continuous activation. EGFR mutations occur for up to 10-15% of all NSCLC patients.14 The EGFR receptor family consists of receptors for a transmembrane tyrosine kinase (TK) which comprises EGFR (also known as HER1 or ERBB1), HER2 (EGFR2 or ERBB2/NEU), HER3 (EGFR3 or ERBB3), and HER4 (EGFR4 and ERBB4).15 EGFR tyrosine kinase inhibitors (gefitinib, erlotinib, and afatinib) are first-line medicines currently available for patients with EGFR-positive mutations with a median initial response rate of 70–80%.16, 17

Many clinicopathological characteristics were observed to associate with the occurrence of EGFR mutations and EGFR gene amplification, including histology of adenocarcinoma, never-smoking background, female sex, and East Asian ethnicity.18 However, most people undergo secondary development of the condition to the developed resistance. T790M pushes up to 60% of the acquired resistance mutations.19 Drugs which inhibit EGFR with the mutation T790 M were established and tested in clinical trials.20 The EGFR TKIs Gefitinib and Erlotinib have tested extensively for NSCLC either independently or in combination with cytotoxic chemotherapy. The results showed that erlotinib extended life relative to best supportive care while gefitinib failed to show a survival benefit.21, 22 Cetuximab, a humanized monoclonal antibody to EGFR extracellular domain, was also studied in NSCLC. the activity was close to that of other line cytotoxics when given to patients with previously diagnosed NSCLC.23 Cetuximab is also being used in patients with resectable level IB–IIIA NSCLC in conjunction with chemoradiation for stage III NSCLC and with neoadjuvant chemotherapy.24

Certain EGFR pathway inhibitors in clinical trials include panitumumab (EGFR targeting), lapatinib (targeting EGFR and HER2), and HK-272 (targeting EGFR and HER2).

3.2 Anti-angiogenic agents

Angiogenesis is one of the hallmarks of cancer, and blocking of receptor-2 (VEGFR-2) vascular endothelin growth factor which blocks the development, propagation and movement of new blood vessels. Several agents are currently under investigation for breaching the VEGF/VEGFR. Among the most tested are monoclonal antibodies against VEGF and the VEGFR TKIs.

According to first-line chemotherapy with carboplatin-paclitaxel, Bevacizumab, a recombinant humanized monoclonal antibody against VEGF, resulted in a significant increase in OS in qualifying patients with non-squamous NSCLC.27 A phase III trial of erlotinib with or without bevacizumab in NSCLC was conducted on the basis of supporting phase I/II research.28, ZD6474 (Zactima) is an oral, dual kinase inhibitor targeting VEGFR-2 and, to a lesser degree, EGFR. In a randomized phase II clinical trial, the application of ZD6474 with docetaxel as a second-line treatment for patients with advanced NSCLC increased progression-free survival compared with docetaxel alone and a confirmatory phase
Ill study has been initiated. Several other VEGFR TKIs and outcomes from phase II lung cancer studies are have shown appropriate safety profiles in phase I studies, predicted.

Table 1: Selected active agents for managing lung cancer in clinical development

| Target                      | Generic Name | Brand Name | Stage of development in cancer |
|-----------------------------|--------------|------------|--------------------------------|
| **EGFR pathway inhibitors** |              |            |                                |
| EGFR                        | Gefitinib    | Iressa     | Approved for advanced NSCLC    |
| EGFR                        | Erlotinib    | Tarceva    | Approved for advanced NSCLC    |
| EGFR                        | Cetuximab    | Erbitux    | Phase II/III                   |
| EGFR                        | Matuzumab    | -          | Phase I                        |
| EGFR, HER2                  | Lapatinib    | Tykerb     | Phase II                       |
| EGFR, HER2                  | HKI-272      | -          | Phase II                       |
| EGFR, HER2, ERB4            | CI-1033      | -          | Phase II                       |
| **VEGF/VEGFR pathway inhibitors** |            |            |                                |
| VEGF-A                      | Bevacizumab  | Avastin    | Approved for advanced NSCLC    |
| VEGFR-2, EGFR               | ZD6474       | Zactima    | Phase II/III                   |
| VEGFR-1-3                   | Vandetanib   | Recentin   | Phase II/III                   |
| VEGFR-1-3, PDGFR, c-KIT, FLT-3 | AZD2171   | Sutent     | Phase II/III                   |
| c-KIT, FLT-3                | SU11248; Sunitinib | -      | Phase II                       |
| VEGFR-1-3, PDGFR-b, c-KIT, c-fms | PTK787; Vatalanib | Champix | Phase II                       |
| VEGFR-1-3, PDGFR, c-KIT     | AG-013736; Axitinib | -   | Phase I                        |
| VEGFR-1-3, PDGFR, c-KIT     | AMG 706      | -          | Phase I                        |
| **Ras/Raf/MEK pathway inhibitors** |            |            |                                |
| Ras                         | -            | Zarnestra  | Phase III                      |
| Ras                         | Tipifarnib (FTI) | Sarasar | Phase III                      |
| Raf-1, VEGFR-2 and -3, PDGFR, c-KIT | Lonafarnib (FTI) | Nexavar | Phase II                       |
| MEK                         | BAY 43-9006; Sorafenib | -     | Phase II                       |
| MEK                         | CI-1040      | -          | Phase I/II                     |
| MEK                         | PD-0325901, AZD6244 | -     | Phase I/II                     |
| **PI3K/Akt/PTEN pathway inhibitors** |            |            |                                |
| mTOR                        | LY294002     | Rapamune   | Phase I                        |
| mTOR                        | Rapamycin; Sirolimus | -  | Phase I/II                     |
| mTOR                        | CCI-779; Temsirolimus | -  | Phase I/II                     |
| Treatment Type          | Target(s)                             | Phase(s) |
|------------------------|---------------------------------------|----------|
| Tumor suppressor gene therapies | p53, p53 retrovirus, p53 adenovirus (Ad5CMV-p53) | Phase I  |
|                        | FUS1 nanoparticle                      | Phase I  |
| Proteasome inhibitors  | Proteasomes, Bortezomib, Velcade       | Phase II |
| HDAC inhibitors        | HDAC, SAHA, Vorinostat, Zolinza        | Phase II |
|                        | HDAC, Depsipeptide                     | Phase I  |
| Telomerase inhibitors  | Telomerase, GRN163L                    | Phase I  |

**Fig 1: New treatments aimed at main oncogenic pathways in lung cancer**
3.3 RAS and MEK Pathway Inhibitors

The protooncogenic RAS family (HRAS, KRAS, and NRAS) codes GTPases associated with 21-kDa plasma membrane that regulate signal transduction pathways affecting the normal differentiation, proliferation and cell survival. Activating RAS mutations are observed in 10%–15% of all NSCLCs (15%–35% of adenocarcinomas) but seldom in SCLCs. KRAS mutations are the most prominent motor modifications, observed in up to 25% of all adenocarcinoma cases. A number of agents have been developed which target different components of the RAS pathway and are being clinically investigated. Among these, farnesyl transferase inhibitors (FTIs) are the most studied, and in lung cancer clinical trials, two orally bioavailable FTIs (tipifarnib and lonafarnib) were tested in combination with cytotoxic therapy.

Targeting KRAS itself was challenging, primarily because KRAS activates multiple downstream effectors, among many others, including MEK. MEK1 inhibitors are currently being tested while defining RAS mutants. Sorafenib is an oral, dual-action, an antiproliferative and antiangiogenic multikinase inhibitor that serves as a powerful inhibitor of RAF kinase and several other receptor TKs including VEGFR-2, VEGFR-3, PDGFR-b, Flt-3, and c-KIT.

MEK inhibitors that aim further downstream along the RAS/RAF pathways have been recently published (CI-1040, PD-0325901, and AZD6244). Preclinical and early clinical trials with these agents demonstrated positive antitumor activity in the treatment of NSCLC, with extended stabilization of the disease recorded in phase I trials in patients with NSCLC.

3.4 PI3K/Akt/PTEN pathway inhibitors

Among human cancers, the PI3K signaling system is often triggered through a sequence of events including activation of upstream receptor TKs (including EGFR and PDGFR) and or PIK3CA mutations, encoding the PI3K catalytic subunit. Preclinical studies of LY294002, a PI3K inhibitor, revealed that the drug improves the responsiveness of NSCLC cells to chemotherapy and radiation, and phase I trials of this agent are in progress. Additionally, several inhibitors of the mammalian target of rapamycin (mTOR), a downstream target of PI3K signaling, were developed. These are rapamycin and its analogs temsirolimus (CCI-779), everolimus (RAD001), and AP23573. During early clinical trials, these compounds have shown positive antitumor activity.

3.5 Tumor suppressor gene therapy

The tumor suppressor p53 is a crucial cellular gatekeeper that is triggered by numerous stress signals such as DNA disruption, oncogenes, and hypoxia, culminating in the expression of downstream genes involving cell-cycle arrest, allowing DNA repair or apoptosis initiation. For lung cancer, the most often mutated gene is p53. p53 is often inactivated by mutation in lung cancer (50% of NSCLCs and 90% of SCLCs). Clinical trials of p53 gene therapy with a retroviral expression vector p53 in NSCLC patients have shown that gene therapy is safe and feasible, with some proof of antitumor activity. FUS1 is a novel gene for tumor suppression located on chromosome 3p21.3, a site usually deleted in lung cancer. Frequent loss of FUS1 protein expression or post-translation protein alteration deficiency has been documented in most of NSCLCs and SCLCs. Further trials are awaited to determine the clinical benefit of these gene therapies in lung cancer.

3.6 Enhancing apoptosis

A central attribute of cancer cells is their capacity to resist apoptosis. Bcl-2 is a crucial anti-apoptotic protein that is over-expressed in 10%–35% of NSCLCs and 75%–95% of SCLCs. Randomized step II trials with oblimersen in conjunction with chemotherapy are ongoing for SCLC and NSCLC. Also, a potent small-molecule inhibitor of the antiapoptotic proteins Bcl-2, Bcl-XL, and Bcl-w was developed (ABT-737) and showed preclinical action against both NSCLC and SCLC.

3.7 Role of immunotherapy

Immunotherapy is a cutting-edge oncology technique that utilizes the body’s own natural defense mechanism to fight cancer. Some cancer cells share characteristics with healthy cells and therefore the immune system cannot differentiate between normal and abnormal (cancer) cells in the body. New immunotherapy strategies are directed at immune-modulating mechanisms that help tumor cells protect themselves against the immune system. Treatments for inhibitory checkpoint molecules like cytolytic T-lymphocyte-associated protein 4 (CTLA4), programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) have all shown therapeutic effectiveness.

Ipilimumab was the first immunotherapeutic to show survival benefits in metastatic melanoma and was approved by the FDA for advanced melanoma care in 2010. The monoclonal antibody nivolumab guided to the PD-1 receptor has demonstrated efficacy through NSCLCs with various histological features. In March 2015, the FDA approved nivolumab for the management of squamous NSCLC. This was accompanied by FDA approval of nivolumab for the non-squamous NSCLC diagnosis. The monoclonal antibody, guided by a PD-1 receptor, pembrolizumab, was approved by the FDA as a second-line treatment in NSCLC in October 2015. The therapeutic efficacies of nivolumab and pembrolizumab have...
been shown to be histologically independent. Smokers and patients with PD-L1-positive expression experience greater benefit\(^5\).

Atezolizumab is a humanized IgG1 monoclonal anti-PD-L1 antibody that prevents association between PD-L1-PD-1 and PD-L1-B7-1, restoring anti-tumor T-cell activity and enhancing T-cell priming. In October 2016 the FDA approved atezolizumab for the treatment of patients with metastatic NSCLC whose cancer worsened during or after platinum-containing chemotherapy. Several trials are ongoing to compare anti-PD-1 and anti-PD-L1 agents, individually and in combination with a cytotoxic T-lymphocyte-associated protein 4 inhibitor (ipilimumab), with platinum-based combination regimens as first-line therapy\(^34\).\(^35\).

### 3.8 Telomerase inhibitors

There is increasing evidence that the enzyme telomerase is upregulated in stem cells of cancer and those telomerase inhibitors can potentially target both stem cells of cancer and more mature cancer cells\(^57\). Chromosomal ends (telomerase) contain hexameric nucleotide repeat tandem tracks of the TTAGGG. During normal cell division, the loss of telomerase activity is associated with incremental shortening of the telomere, contributing to cell senescence and normal cell death\(^58\). Telomerase is expressed almost universally in human tumors, whereas in normal tissue telomerase activity is reduced or absent. Detectable amounts of telomerase are present in approximately 80% of NSCLCs and 100% of SCLCs\(^58\). GRN163L is a novel telomerase antagonist designed to target the hTR RNA template region. Preclinical studies have shown that GRN163L inhibits anchorage-independent growth and the development of lung cancer cells in vivo xenograft tumors\(^59\), and phase I trials with this agent are underway. Several other drugs are currently under development that targets telomerase, including immunotherapy (vaccines), gene therapy (telomerase oncolytic virus therapy), and inhibitors of reverse transcriptase.

### 4 Radiotherapy

Stereotactic ablative radiotherapy (SABR) has become a treatment option for patients with early-stage node-negative NSCLC patients who are not surgical candidates or who reject surgical options\(^60\). In addition to the importance of radiotherapy in stage I NSCLC, new studies have investigated its role in the treatment of stage IV NSCLC in conjunction with chemotherapy, and have shown increased survival when primary tumor radiotherapy was implemented.

Radiotherapy has also shown interest in improving contact with CNS. Depending on the volume and amount of brain metastases, stereotactic radiation is often compared to whole-brain radiation therapy (WBRT), when possible, mostly due to fewer neurological side effects. With WBRT a higher response rate is noted in patients with EGFR- mutant NSCLC with brain metastasis. Despite these results, many practitioners and patients avoid WBRT to prevent hair loss, tiredness and WBRT neurocognitive sequelae\(^61\). In patients with oligoprogressive disorder with EGFR tyrosine kinase inhibitor monotherapy, local radiotherapy or surgical resection is advised on a case-by-case basis with continuity of the EGFR tyrosine kinase inhibitor\(^62\).

### 5 Surgical therapy

Surgery is the main therapy for patients with non–small-cell lung cancer, especially early disease patients. Surgery may include resection (pneumonectomy or lobectomy) and regeneration of the mediastinal node. Total dissection of the lymph-node should be performed when the tumor becomes resectable and mediastinal nodes are concerned\(^63\).

### 6 Chemotherapy

Around 40% of newly diagnosed patients with lung cancer are in stage IV. The aim of treating these patients is to improve their survival and reduce the adverse effects associated with the disease. Many chemotherapeutic agents are effective against both small-cell and non–small-cell lung cancer (Table 2). Among the most active are those of the platinum family: cisplatin, which cross-links DNA, and carboplatin, a cisplatin analog\(^64\),\(^65\).

Chemotherapy adverse effects can be severe but are usually manageable and reversible. Major effects include nausea, vomiting, alopecia, myelosuppression, nephrotoxicity, neuropathy, loss of hearing at high tones, and depletion of electrolytes. Etoposide, docetaxel, paclitaxel, gemcitabine, vinorelbine, and irinotecan are often used in conjunction with a platinum agent.

### 7 Conclusion

Significant progress has been made in reducing the occupational health risks correlated with lung cancer, in particular smoking, and to avoid numerous disorders. Intense research in translational oncology over the last decade has provided important insights into the molecular basis of carcinogenesis and human cancer biological behavior. Based on this information, new strategies have been created for screening, early diagnosis, prevention, staging, and therapy which show promise to enhance the management of lung cancer. Targeted therapy and immunotherapy have made important contributions in recent decades, to better lung cancer management. Progress in lung cancer therapy has been sluggish yet gradual, and has improved thanks to changes in the disease’s medical base and testing and care technical advancements. Continued interdisciplinary research efforts will accomplish the ambitious target of reducing mortality rates in the next 50 years.

### 8 Conflict of interest

The author’s declares that there is no conflict of interest.

### 9 Author's contribution

Khan et al., Targeted Therapies For Treatment of Lung Cancer Pharm & Biosci J. 2020: 8(3); 27
Table 2: Chemotherapy for Lung Cancer

| Drug                  | Type of Agent      | Major adverse effect                                                                 |
|-----------------------|--------------------|---------------------------------------------------------------------------------------|
| **Platinum agents**   |                    |                                                                                       |
| Cisplatin (Platinol)  | Atypical alkylator | Nausea and vomiting (common), nephrotoxicity, ototoxicity, neuropathy, myelosuppression (mild), electrolyte wasting (potassium and magnesium) |
| Carboplatin (Paraplatin) | Atypical alkylator | Myelosuppression, nausea, and vomiting (mild), neurotoxicity (rare), nephrotoxicity (rare) |
| **Nonplatinum agents**|                    |                                                                                       |
| Etoposide (VePesid)   | Topoisomerase II Inhibitor | Myelosuppression, nausea, vomiting, stomatitis, diarrhea                            |
| Topotecan (Hycamptin) | Topoisomerase I inhibitor | Myelosuppression, nausea, vomiting, diarrhea, headache                                  |
| Irinotecan (Camptosar) | Topoisomerase I inhibitor | Myelosuppression, diarrhea, nausea, Vomiting                                            |
| Gemcitabine (Gemzar)  | Antimetabolite      | Myelosuppression, nausea, vomiting, diarrhea, edema, influenza-like syndrome            |
| Paclitaxel (Taxol)    | Microtubule Inhibitor | Myelosuppression, mucositis, peripheral neuropathy, hypersensitivity reaction, nausea and vomiting |
| Docetaxel (Taxotere)  | Microtubule inhibitor | Myelosuppression, edema & fluid retention, mucositis, diarrhea, nausea, vomiting       |
| Vinorelbine (Navelbine) | Microtubule Inhibitor | Myelosuppression, nausea, vomiting                                                     |
| Vincristine (Oncovin) | Microtubule inhibitor | Neuropathy, constipation                                                               |
| Doxorubicin (Adriamycin) | Anthracycline antibiotic | Myelosuppression, cardiomyopathy, nausea, vomiting, diarrhea, stomatitis           |
| Cyclophosphamide (Cytoxan) | Alkylating agent | Myelosuppression, nausea, vomiting, hemorrhagic cystitis                                 |
| Ifosfamide (Ifex)     | Alkylating agent    | Myelosuppression, nausea, vomiting, hemorrhagic cystitis, nephrotoxicity, neurotoxicity |

10 References

1. Sun X, Roudi R, Chen S, Fan B, Li HJ, Zhou M. Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: protocol for a systematic review and meta-analysis. Medicine. 2017; 96(44): 8407.

2. Fauci AS. Harrison's Principles of Internal Medicine Companion Handbook. Literature in Bioethics. 1998.

3. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995; 75(12): 2844-52.

4. Kenfield SA, Wei EK, Stampfer MJ, Rosner BA, Colditz GA. Comparison of aspects of smoking among the four histological types of lung cancer. Tobacco Control. 2008;17(3):198-204.

5. Rekhtman N, Tafe LJ, Chaft JE, Wang L, Arcila ME, Colanta A. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Modern Pathology. 2013;26(4):511-22.
6. Punnonen K, Hietanen E, Auvinen O, Punnonen R. Phospholipids and fatty acids in breast cancer tissue. Journal of Cancer Research and Clinical Oncology. 1989;115(6):575-8.

7. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. British Journal of Cancer. 2005;93(7):825-33.

8. Whitrow MJ, Smith BJ, Pliotto LS, Pisaniello D, Nitschke M. Environmental exposure to carcinogens causing lung cancer: epidemiological evidence from the medical literature. Respiration. 2003;66(4):513-21.

9. Jones SE, Foster S, Berens AS. Radon testing status in schools by radon zone and school location and demographic characteristics: United States. The Journal of school Nursing. 2014. 2019; 35(6): 442-8.

10. Engl N. Survival of patients with stage I lung cancer detected on CT screening. The International early Lung Cancer Action program Investigators. Medicine. 2006;85(17):1763-71.

11. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. Journal of Thoracic Oncology. 2007;2(4):327-43.

12. Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer research. 2005;65(17):7568-72.

13. Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino U. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clinical Cancer research. 1999; 5(10): 2689-92.

14. Cadranel J, Ruppert A-M, Beau-Faller M, Wislez M. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Clinical reviews in oncology/Hematology. 2013; 88(3): 477-93.

15. Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annual Reviews of Medicine. 2004; 55: 433-57.

16. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non–small-cell lung cancer. Current knowledge and future directions. Journal of Clinical Oncology. 2005; 23(11): 2556-68.

17. Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. Journal of Thoracic Oncology. 2007; 2(5): 430-9.

18. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLOS medicine. 2005; 2(3): 73.

19. Socinski MA, Evans T, Gettering S, Hensing TA, Sequist LV, Ireland B. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. CHEST. 2013;143(5): 341S- 368S.

20. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Research. 2005; 65(16): 7096-101.

21. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S. Erlotinib in previously treated non–small-cell lung cancer. The New England jourenal of Medicine. 2005;353(2):123-32.

22. Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, Von Pawel J. Gefitinib plus best supportive care in previously treated non–small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). The Lancet. 2005; 366(9496): 1527-37.

23. Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jänne PA. Phase II trial of cetuximab in patients with previously treated non–small-cell lung cancer. Journal of Clinical Oncology. 2006; 24(33): 5253-8.

24. Werner-Wasik M, Swann S, Curran W, Robert F, Komaki R, Lee C. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): an interim overall toxicity report of the RTOG 0324 trial. Journal of Clinical Oncology. 2005;23(16):7135.

25. Coate LE, Gately K, Barr M, Meaney J, O’Connell F, Nicholson S. Phase II pilot study of neoadjuvant cetuximab in combination with cisplatin and gemcitabine in patients with resectable IB–IIIA non
small cell lung cancer. Journal of Clinical Oncology. 2006;24(18):17107.

26. Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014;508(7495):222-7.

27. Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. The Lancet. 2016;17(7):984-93.

28. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non–small-cell lung cancer. Journal of Clinical Oncology. 2005;23(11):2544-55.

29. Heymach J, Johnson B, Prager D, Csada E, Roubec J, Pesek M, et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. Journal of Clinical Oncology. 2006;24(18):7016.

30. Downward J. Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer. 2003;3(1):11-22.

31. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annual review of Medicine. 2003;54(1):73-87.

32. Isobe T, Herbst RS, Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. Seminars in oncology. 2005;32(3): 315-328.

33. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069-75.

34. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clinical Cancer Research. 2008;14(18):5731-4.

35. Yip PY, Yu B, Cooper WA, Selinger CI, Ng CC, Kennedy CW. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma. Journal of Thoracic oncology. 2013;8(4):408-14.

Khan et al., Targeted Therapies For Treatment of Lung Cancer

36. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research. 2004;64(19):7099-109.

37. LoRusso PM, Adjei AA, Var特斯ian M, Gadgeel S, Reid J, Mitchell DY. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. Journal of Clinical Oncology. 2005; 23(23): 5281-93.

38. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nature Reviews Cancer. 2002;2(7):489-501.

39. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Research. 2001;61(10):3986-97.

40. Olivero M, Rizzo M, Madeu dd R, Casadio C, Pennacchietti S, Nicotra M. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. British Journal of Cancer. 1996;74(12):1862-8.

41. Hainaut P, Hernandez T, Robinson A, Rodriguez TP, Flores T, Hollstein. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic acids Research. 1998;26(1):205-13.

42. Roth JA, Nguyen D, Lawrence D, Kemp B, Carrasco C, Ferson D. Retrovirus–mediated wild-type P53 gene transfer to tumors of patients with lung cancer. Nature Medicine. 1996;2(9):985-91.

43. Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C. Expression of several genes in the human chromosomal 3p21. 3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Research. 2002;62(9):2715-20.

44. Kondo M, Ji L, Kamibayashi C, Tomizawa Y, Randle D, Sekido Y. Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21. 3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene. 2001;20(43):6258-62.

45. Hanahan D. Hallmarks of cancer: a 2012 perspective. Annals of oncology. 2012;23(9):ix23.
In vivo inhibition of lung cancer
rieta O, Prabhash K, Tansend. Therapy for first Cal Oncology. Randomised 56. 55. 54. 53. 52. 51. 50. 49. 48. 47. 46. Borghaei H, Gettinger S. Nivolumab in combination with programmed death-1 (PD-1) inhibition for previously untreated stage III/IV non–small-cell lung cancer: results from the Checkmate 032 (KEYNOTE-001) study. The Lancet. 2016;387(10027):1540-1548.

Borghaei H, Paz AL, Horn L, Spigel DR, Steins M, Ready NE. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. The New England Journal of Medicine. 2015;373(2):123-135.

Borghaei H, Paz AL, Horn L, Spigel DR, Steins M, Ready NE. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. The New England Journal of Medicine. 2015;373(17):1627-1636.

Herbst RS, Baas P, Kim DW, Felip E, Pérez GJL, Han J-Y. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 2016;387(10027):1540-1550.

Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. Clinical Cancer research. 2012;18(24):6580-6587.

Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non–small-cell lung cancer. Journal of Clinical Oncology. 2016;34(25):2969.

Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nature Reviews drug Discovery. 2006;5(7):577-584.

Hiyama K, Hiyama E, Iishioka S, Yamakido M, Inai K, Gazdar AF. Telomerase activity in small-cell and non–small-cell lung cancers. Journal of the National Cancer Institute.1995;87(12):895-902.

Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer research. 2005;65(17):7866-7873.

Coyne GOS, Madan RA, Gulley JL. Nivolumab: promising survival signal coupled with limited toxicity raises expectations. Journal of Clinical Oncology. 2014;32(10):986.

Ram M, Singh V, Kumawat S, Kant V, Tandan SK, Kumar D. Bilirubin modulated cytokines, growth factors and angiogenesis to improve cutaneous wound healing process in diabetic rats. International Immunopharmacology. 2016;30:137-149.

Khan et al., Targeted Therapies For Treatment of Lung Cancer
with platinum-based doublet chemotherapy for first-line treatment of advanced non–small-cell lung cancer. Journal of Clinical Oncology. 2016;34(25):2969.

Pharm & Biosci J. 2020; 8(3); 31